Bispecific antibody · Immune activation, directed at delta-like protein 3 (DLL3) and CD3 (CD3E) · developed by Boehringer Ingelheim
Obrixtamig is a bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on cytotoxic T-lymphocytes. By bringing these T cells to DLL3-expressing cells, it triggers T-cell-mediated death of those tumor cells. It is studied in small cell lung cancer and related neuroendocrine lung and extrapulmonary carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07707895 | Phase 1/2 | Small Cell Lung Cancer | Recruiting | ZLAB |
| NCT07843940 | Phase 1/2 | Extensive-stage Small Cell Lung Carcinoma | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Small Cell Lung CancerExtensive-stage Small Cell Lung CarcinomaLarge Cell Neuroendocrine Lung CarcinomaSmall Cell Lung Cancer